"Pharmaceutical Speed Reader" step-by-step pharmaceutical sales of Hubei Kyushu Tong equity a number of pharmacies to write off the de-listing.

Step Pharmaceuticals intends to transfer the shares of Hubei Step Long Kyushu Tong, Heng Rui and Sun Yiyang jointly invested 100 million yuan to set up a new company, and Regenerative Yuan Launch Antibody Cocktail Therapy Phase 3 Clinical for the prevention of new crown virus infectionOn june 6, the Fujian Provincial Drug Administration issued a "notice on the issuance of special work programme for the issuance of Chinese medicine tablets." "Notice" pointed out that in order to implement the new version of the Drug Administration Law to improve the quality of Chinese medicine tablets, Fujian Province will carry out a year and a half of Special Treatment of Chinese Medicine tablets(Fujian Provincial Drug Administration)the Guangxi Autonomous Region Health and Health Commission and other seven departments issued "on the further good management of medical institutions to promote the work of rational drug use notice." "Notice" requires public medical institutions at all levels to quickly check the pharmaceutical service work irregularities, especially the relevant situation of pharmacy custody, the formulation of anti-correction programs, clear task division and time progress, solid completion of the work of inspection and correction(Guangxi Autonomous Region Health and Health Commission, etc.)the official website of the Guangdong Provincial Drug Administration forwarded the announcement of the Zhanjiang Xiashan District Marketing Bureau on the cancellation of the Drug Business LicenseAccording to the announcement, according to the Guangdong Food and Drug Administration's Regulations on the Cancellation of Drug Licenses (Guangdong Food and Drug Supervision Law (2013) No26), from January 1, 2019 to June 30, 2020, the Bureau has cancelled the "Drug Business License" of 100 enterprises, such as Xinjianmin Pharmacy in Xiashan District, Zhanjiang City, according to law(Guangdong Provincial Drug Administration)Step Pharmaceuticals announced that, in order to optimize the company's asset structure, the company held the 33rd (interim) meeting of the third board of directors on July 6, 2020, to consider and approve the "on the company's proposed transfer of shares in the holding subsidiary of the holding subsidiary of Hubei Step, Kyushu Tong 51% of the shares to Kyushu Tong Pharmaceutical Group Co., Ltdat a price of 21.7523 million yuan." (Sina Pharmaceutical News)Hengrui Pharmaceuticals announced that its wholly-owned subsidiary Shanghai Hengrui intends to co-finance the establishment of Reilly (Shanghai) Biopharmaceutical Co., Ltd(Ruilidi), a natural person associated with Hengrui, Jiangsu ProvinceReedi's registered capital is RMB10 million, of which Shanghai Hengrui has paid 60 million yuan, accounting for 60% of the registered capital, and MrSun has paid 40 million yuan, accounting for 40% of the registered capitalReilly is responsible for the research and development, production, sales and related import and export business of antiviral therapy(Hengrui Pharmaceutical Bulletin)6, Regenerative Yuan announced the launch of a Phase 3 clinical trial to assess the company's development of the new crown virus biantibody cocktail therapy RGEN-COV2, in the uninfected population to prevent the new coronavirus infectionThese people have had close contact with PATIENTs with COVID-19Regenerative Yuan will conduct this clinical trial in collaboration with the National Institutes of Allergy and Infectious Diseases, a subsidiary of the National Institutes of HealthAt the same time, the adaptive clinical trial for REGN-COV2 treatment of inpatient and non-inpatient COVID-19 patients also entered Phase 2/36, clinical-phase biopharmaceutical company Bellus Health released the top-line analysis of RELIEF in a Phase 2 clinical trial of the drug BLU-5937 for patients with refractive chronic coughThe data showed that any dose of BLU-5937 reduced the time of placebo-adjusted cough was not statistically significant and did not reach the primary endpoint(Sina Pharmaceutical News)Cellectis recently announced that its clinical trial MELANI-01 has been suspended by the U.SFDAThe company's shares fell 18 percent on the news(Sina Pharmaceutical News), The Company of California, Announced the positive results of two Phase 3 clinical trials (PRIMROSE 1 and PRIMROSE 2) developed and sold to improve new treatments for women's reproductive health, announcing its star product, Yselty ® (linzagolix), for uterine fibroids(SINA Pharmaceutical news)July 6 local time, Swiss pharmaceutical company Idorsia released its double orexin receptor antagonist (DORA) daridorexant's second phase 3 clinical data for insomniac patients, overall, the results are mixed(Sina Pharmaceutical News)OfDDDeDs announced that the antibody conjugate drug Trodelvy, developed by the company, reached the primary endpoint of progression-free survival in a confirmed phase 3 ASCENT clinical trial for patients with metastatic triple-negative breast cancer, reducing the risk of disease progression or death by 59 percent Trodelvy has previously received FDA accelerated approval based on objective mitigation rates and mitigation duration data in a single arm 2 clinical trial The company plans to submit a supplemental biologics license application to the FDA based on this phase 3 clinical data, seeking full approval for Trodelvy The ViiV Healthcare recently released preliminary positive results from the CUSTOMIZE study The purpose of the study was to determine the successful application of the monthly long-acting injection regimen cabotegravir/rilpivirine (CAB/RPV, Cabotwe/Lipivirin) to clinical practice (Bio Valley) the website of the Drug Review Center of the State Drug Administration of China, GlaxoSmithKline has submitted a listing application for mepolita (generic name: mepolizumab, commodity name: Nucala) in China, which was accepted on July 6 (Pharmaceutical MingKang) recently, Dongsun drug's Liglitin tablets (acceptance number CYHS1800162) imitation 4 categories of listing applications into the administrative approval stage, the first imitation is about to be taken According to Minnet.com, sales of Ligretin tablets at the end of China's public medical institutions in 2019 were 246 million yuan It is worth mentioning that since the domestic listing of Ligretin tablets in the domestic market sales, the annual growth rate of more than 100% (Minnet.com) China Biopharmaceuticals announced that the Group developed a body fluid and energy supplement "converted sugar injection" (commodity name: Feng Haixin) has been issued by the State Drug Administration of China drug registration approval (Sina Pharmaceutical News) 6, Endo International announced the U.S FDA approval Qwo (collagenase cridium histolyticum-aaes, the lysophynosis Clostridium aelyse), used to treat adult female hip moderate to severe cellular tissue inflammation (orange skin tissue, commonly known as cell ulas) Qwo is the first FDA-approved injection to treat orange peel AstraZeneca, , has announced that its drug Forxiga (Chinese product name: Andatang, generic name: dapagliflozin, Dagrenet) has been approved for a new indication in India to treat adult patients with heart failure (HFrEF) with reduced blood score (Biological Valley) Cancer Prevention Pharmaceuticals recently announced that it has submitted a new drug application to the U.S FDA to seek accelerated approval of CPP-1X/sul for the treatment of adult familial adenoma polyps Recently, CPP also submitted a marketing authorization application for CPP-1X/sul for the same indications to the European Medicines Agency In the United States and the European Union, the drug is granted orphan status In the United States, it has also been granted fast-track status (Bio Valley)